Novo Nordisk mark World Haemophilia Day and unveil the 2016 HERO Research Grant

Zürich, Switzerland (ots/PRNewswire) -

This material is intended for global medical media only.

For journalistic assessment and preparation before publication.

Today, on World Haemophilia Day, Novo Nordisk announces that the
grant scheme to support and encourage research projects focused on
the psychosocial issues faced by people with haemophilia is open for
applications. The scheme, Haemophilia Experiences, Results, and
Opportunities (HERO) Research Grant is worth up to EUR75,000, and
aims to create awareness of the challenges faced by people living
with haemophilia.

As part of the global campaign, 'Meet the HERO', Novo Nordisk also
calls on the haemophilia community to celebrate the everyday heroes
of haemophilia by tweeting a photo or video of how they take part in
World Haemophilia Day using the hashtags #MeetTheHERO and #WHD2016.

"The HERO research grant is part of our commitment to helping
people with haemophilia live a life with fewer limitations and
support the heroes who care for them," says Paul Huggins, Corporate
Vice President, Global Biopharm, Zürich, Novo Nordisk.

'Meet the HERO' supports the World Federation of Haemophilia (WFH)
campaign, 'Treatment for all, the vision of all', and is part of Novo
Nordisk's long-term commitment to changing haemophilia. This campaign
uses insights from the ground-breaking HERO study that provides
evidence about what it is like to live with haemophilia and calls for
better psychosocial support for people with haemophilia, their
families and those who care for them.

The HERO research grant is available to healthcare professionals
providing care for people with haemophilia, and social workers or
similar who provide or have expertise in psychosocial support for
people with haemophilia.

For more information and to apply, please visit
http://www.herostudy.org.

This World Haemophilia Day, show your support for the heroes of
haemophilia with a tweet, photo or video of how you take part in the
day by using #MeetTheHero and #WHD2016

About Haemophilia

Haemophilia is a rare blood clotting disorder. Internal bleeding
into the joints, muscles, and other tissues can cause severe pain,
joint damage, and disability. The worldwide incidence of haemophilia
A is approximately one case per 5,000 males, approximately 30 per
cent of whom have no family history. Haemophilia B occurs in one case
per 25,000 males and represents 20-25 per cent of all patients with
haemophilia. Globally, it is estimated that 440,000 people have
haemophilia.

About World Haemophilia Day

Since 1989, patient groups worldwide have annually marked World
Haemophilia Day on 17 April to raise awareness and understanding of
haemophilia and other bleeding disorders. The date was chosen in
honour of the World Federation of Haemophilia founder Frank Schnabel,
who was born on that day.

About the HERO Study

Haemophilia Experiences, Results, and Opportunities (HERO) is an
international, multidisciplinary initiative led by the HERO
International Advisory Board and supported by Novo Nordisk as part of
its Changing Haemophilia(TM) programme. It encompasses the
psychosocial experiences of people with haemophilia, their families,
and their health care providers and covers themes such as employment,
relationships, sexual health, treatment and management of
haemophilia, information and knowledge, and quality of life.

Changing Haemophilia(TM)

For more than three decades, Novo Nordisk has been committed to
Changing Haemophilia(TM). In addition to the discovery and
development of effective and safe biological medicines, we work with
our global partners to advocate for and create better access to
diagnosis and multidisciplinary care with a focus on joint health. We
aim for a future where all people living with haemophilia can live a
life with as few limitations as possible.

About Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare
company with 90 years of innovation and leadership in diabetes care.
The company also has leading positions within haemophilia care,
growth hormone therapy and hormone replacement therapy. Novo Nordisk
employs approximately 41,000 employees in 75 countries, and markets
its products in more than 180 countries. For more information, visit
novonordisk.com (http://novonordisk.com).

Further information
Media:

Katrine Sperling

+45-4442-6718

krsp@novonordisk.com

Åsa Josefsson

+45-30797708

aajf@novonordisk.com
Investors:

Peter Hugreffe Ankersen

+45-3075-9085

phak@novonordisk.com

Melanie Raouzeos

+45-3075-3479

mrz@novonordisk.com

Daniel Bohsen

+45-3079-6376

dabo@novonordisk.com

Kasper Veje

+45-3079-8519

kpvj@novonordisk.com

ots Originaltext: Novo Nordisk A/S
Im Internet recherchierbar: http://www.presseportal.de